Publication | Closed Access

Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract

VaccinationViral DiagnosticsRespiratory DiseasesUltra-potent AntibodyImmunologyRespiratory InfectionLower Respiratory TractVirologyInfectious Respiratory DiseaseMedicine